Search

everythinglearnresearchcommunity

for

Search:↓

Using fractional CO2 laser with halometasone cream works better for chronic hand eczema than just the cream, improving symptoms and quality of life with fewer relapses.

Venusia CeraPlus cream and lotion effectively reduce eczema severity and improve skin moisture.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Vitiligo patients are willing to pay the most for treatment, regardless of disease severity.

High retinol intake may worsen hair loss in alopecia areata.

Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Patients with certain skin diseases are willing to spend significant time on treatment, indicating a high impact on their lives and a need for better treatments.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Patients with ichthyosis often experience symptoms similar to psoriasis and atopic dermatitis, suggesting that targeted therapies could improve their condition.

Atopic dermatitis significantly lowers the quality of life for infants and their families.

A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.

Pontianak Aloe Vera is beneficial for skin and hair care in various cosmetic products.

Dupilumab improves skin microbiome balance in atopic dermatitis patients.

Children with metabolic syndrome often have skin problems like dark patches, skin tags, stretch marks, infections, acne, and psoriasis, which are linked to obesity and insulin resistance.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Higher BMI may increase the risk of psoriasis and some other skin diseases.

Women with PCOS are at high risk of glucose metabolism issues and heart diseases, especially if overweight, highlighting the need for early intervention.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

There is a significant need for better-validated quality of life tools in dermatology.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.

Higher ACE2 levels in certain tissues may worsen COVID-19 in people with other health issues, especially older adults.

Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.

Korean Red Ginseng may improve skin condition and reduce allergy markers in atopic dermatitis patients.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.